Pfizer Corporation

Mehran Jalaie

Sajiv Krishnan Nair

Ping Chen

Eugene Yuanjin Rui

Robert Steven Kania

Cynthia Louise Palmer

Sacha Ninkovic

Suvi Tuula Marjukka Orr

Gary Michael Gallego

Martin James Wythes

Judith Gail Deal

Ryan Patman

Sujin Cho-Schultz

Ketan Satish Gajiwala

Kevin Daniel Freeman-Cook

Indrawan James McAlpine

Douglas Carl Behenna

Dahui Zhou

John Charles Kath

Hengmiao Cheng

Andreas Maderna

Robert Louis Hoffman

Ru Zhou

Jamison Bryce Tuttle

Andrew Fensome

Asako Nagata

Michele Ann McTigue

Mingying He

Chan Woo Huh

Martha Alicia Ornelas

Rebecca Anne Gallego

Anne-Marie Dechert Schmitt

Matthew L Del Bel

Lei Zhang

Kimberly O Cameron

Samit Kumar Bhattacharya

Liying Zhang

John M Curto

Martin Youngjin Pettersson

Matthew Forrest Sammons

Mason Alan Pairish

Ted William Johnson

Hong Shen

Tuan Phong Tran

Qingyi Yang

Omar Khaled Ahmad

Yajing Lian

Luke Raymond Zehnder

Ethan Lawrence Fisher

Joyann Barber

Jianmin Sun

Indrawan James Mcalpine

Suvi Tuula Orr

Ketan S Gajiwala

Michele Ann Mctigue

This invention relates to compounds of Formula (I)

Cyclin dependent kinase inhibitors

Modulators of STING (stimulator of interferon genes)

Provided herein are compounds of the general formula (I): and pharmaceutically acceptable salts thereof, processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.

This invention relates to compounds of general Formula I

Azalactam compounds as HPK1 inhibitors

This invention relates to compounds of general Formula (I) 

CDK2/4/6 inhibitors

This invention relates to compounds of Formula (I) or a pharmaceutically acceptable salt thereof, in which R-groups Rto R, A, Q, U, V, W, X, Y, Z, n, p and q are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject.

This invention relates to compounds of general Formula I in which A, R, R, Rand Rare as defined herein, and the pharmaceutically acceptable salts thereof; to pharmaceutical compositions comprising such compounds and salts; to methods of using such compounds, salts and compositions for treating pulmonary hypertension and related diseases, like pulmonary arterial hypertension; to methods of using such compounds, salts and compositions for treating abnormal cell growth, such as cancer; and to processes to make such compounds, salts and compositions.

Anti-proliferative agents for treating PAH

Compounds of the general formula (I): or a pharmaceutically acceptable salt thereof, processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.

Cyclopentane-based modulators of STING (stimulator of interferon genes)

This invention relates to compounds of Formula (I) 

The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein X, Y, Z, R-R, m, n, and p are defined herein. The novel pyrimidine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. Additional embodiments relate to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in mammals.

Pyrimidine derivatives

The present invention relates to compounds of formula (X) 

Dihydropyrrolopyrimidine derivatives

Growing community of inventors

San Diego, CA, United States of America

Mehran Jalaie